Collaborative Arrangement Additional UpFront Payment To Be Received

No definition available.

Name:	ptla_CollaborativeArrangementAdditionalUpFrontPaymentToBeReceived
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangement up front payment to be received.

+ References

No definition available.

+ Details

Name:	ptla_CollaborativeArrangementUpFrontPaymentToBeReceived
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent consideration of collaboration arrangement.

+ References

No definition available.

+ Details

Name:	ptla_ContingentConsiderationOfCollaborationArrangement
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cost Sharing Percentage

+ References

No definition available.

+ Details

Name:	ptla_CostSharingPercentage
Namespace Prefix:	ptla_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

License fee receivable upon occurrence of certain development and regulatory events.

+ References

No definition available.

+ Details

Name:	ptla_LicenseFeeReceivableUponOccurrenceOfCertainDevelopmentAndRegulatoryEvents
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non contingent consideration being recognized as revenue over estimated period of performance.

+ References

No definition available.

+ Details

Name:	ptla_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Notice Period For Agreement Termination

+ References

No definition available.

+ Details

Name:	ptla_NoticePeriodForAgreementTermination
Namespace Prefix:	ptla_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduction To Research And Development Expense

+ References

No definition available.

+ Details

Name:	ptla_ReductionToResearchAndDevelopmentExpense
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront fee subject to refund.

+ References

No definition available.

+ Details

Name:	ptla_UpfrontFeeSubjectToRefund
Namespace Prefix:	ptla_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Collaboration and License Agreements - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended	1 Months Ended			3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Nov. 30, 2012 Biogen Idec	Jun. 30, 2013 Biogen Idec	Jun. 30, 2012 Biogen Idec	Jun. 30, 2013 Biogen Idec	Jun. 30, 2012 Biogen Idec	Sep. 30, 2013 Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")	Jun. 30, 2013 Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer") Collaborative Arrangement	Jun. 30, 2012 Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer") Collaborative Arrangement	Jun. 30, 2013 Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer") Collaborative Arrangement	Jun. 30, 2012 Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer") Collaborative Arrangement	Jan. 31, 2013 Lee's Pharmaceutical (HK) Ltd ("Lee's")	Jun. 30, 2013 Lee's Pharmaceutical (HK) Ltd ("Lee's") Collaborative Arrangement	Jun. 30, 2013 Lee's Pharmaceutical (HK) Ltd ("Lee's") Collaborative Arrangement	Jun. 30, 2013 Aciex Therapeutics, Inc. (Aciex)	Jun. 30, 2013 Aciex Therapeutics, Inc. (Aciex)	Feb. 01, 2013 Bayer Pharma AG	Feb. 01, 2013 Janssen Pharmaceuticals, Inc.	Feb. 01, 2013 Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")	Jun. 30, 2013 Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen") Collaborative Arrangement	Jun. 30, 2012 Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen") Collaborative Arrangement	Jun. 30, 2013 Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen") Collaborative Arrangement	Jun. 30, 2012 Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen") Collaborative Arrangement	Jun. 30, 2013 Daiichi Sankyo, Inc. ("Daiichi")	Jun. 30, 2013 Daiichi Sankyo, Inc. ("Daiichi") Collaborative Arrangement	Jun. 30, 2013 PORTOLA PHARMACEUTICALS INC
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee receivable upon occurrence of certain development and regulatory events					$ 370,000,000
Notice period for agreement termination					120 days										60 days
Reduction in research and development expense						164,000	2,100,000	494,000	4,800,000
Deferred revenue										6,000,000	900,000		900,000			648,000	648,000						2,600,000		2,600,000			2,900,000
Collaboration revenue recognized											1,100,000		3,100,000			52,000	52,000						1,300,000		2,400,000			125,000
Upfront and non-refundable fee															700,000					2,500,000	2,500,000	5,000,000
Development costs, percent																			60.00%										40.00%
Research and development	20,833,000	13,088,000	38,556,000	26,049,000														0	0
Additional upfront and non-refundable fee																				250,000	250,000	500,000
Collaborative arrangement up front payment to be received																											6,000,000
Upfront fee subject to refund																											3,000,000
Contingent consideration of collaboration arrangement																												3,000,000
Non-contingent consideration being recognized as revenue over estimated period of performance																												$ 3,000,000